


## FIGURE 1

1 2 3 4 5 6 7 8




$\beta$ -actin

## FIGURE 2



IL-10---

## FIGURE 3



## FIGURE 4




FIGURE 5A

1 2 3 4 5






FIGURE 5B

1 2 3 4 5



# FIGURE 6



# FIGURE 7

	<b>Leader -----</b>	
RAT	ATGGGCAGTCCGGTATTTCAGGAGACCTTTCTGCCATCTGTCCACCTACAGCCTGCTCTGGGCCATAG	67
MOU	-----T-----C-----A-T---G-----	67
HUM	--GA-----TG---C---CT-----T-----G-T---T---G-	55
	<b> V-like domain -----</b>	
RAT	CAGCAGTAGCGCTGAGCACAGCTCAAGTGGAAGTGGTGACCCAGGATGAAAGAAAGCTGCTGCACAC	134
MOU	-----GC-----	134
HUM	-----G-T---T-----A-----C-----A---T---	122
RAT	AACTGCATCCTTACGCTGTTCTCTAAAAACAACCCAGGAACCCCTTGATTGTGACATGGCAGAAAAAG	201
MOU	-----A-----T-----	201
HUM	-----T-----AAA-C---GC---ATG-----G---C-C-----	189
RAT	AAAGCCGTAGGCCAGAAAACATGGTCACTTACAGCAAAGCCCATGGGGTTGTCACTCAGCCACCT	268
MOU	-----GA-----C-----A---A---C---TG---	268
HUM	-----T---A-----C-T---G-GAA-----G---G---C---TG---	256
RAT	ACAAAGACAGGATAAACATCACTGAGCTGGGACTCTTGAACACAAGCATCACCTTCTGGAACACAAC	335
MOU	-----TG---A-----G---T-----CA	335
HUM	-T-G---A-----T-CC-----C-A---T---C-----T-TC--	323
RAT	CCTGGATGATGAGGGTTGCTACATGTGTCTCTTCAACATGTTTGGATCTGGGAAGGTCTCTGGGACA	402
MOU	-A-T-GA---GA-C-----C-----T---CA-----A-A---	402
HUM	-----G---A-G-T-----T-CC-----T-T-----A-A-G	390
	<b> C-like domain -----</b>	
RAT	GCTTGCCTTACTCTCTATGTACAGCCCATAGTACACCTTCACTACAACCTATTTTGAAGACCACCTAA	469
MOU	-----C-----	469
HUM	--C---C---CG-----TC-----A-TC-C-----	457
RAT	ACATCACGTGCTCTGCAACTGCCCGCCAGCCCTGCCATCTCCTGGAAGGGCACTGGGTGAGGAAT	536
MOU	-----T-----G-----T-----A-----T---A-----	536
HUM	-T---T-----C-----CATGG---T-----T-C-C-----	524
RAT	TGAGAATAGTACTGAGAGTCACTCCCATTCAAATGGGACTACATCTGTCAACAGCATCCTCCGGGTC	603
MOU	-----C-----T-----	603
HUM	---A-----A-T---C---TG---T---CC-----C---G---T-----ATA--	591
RAT	AAAGACCCCAAACTCAGGTTGGAAAGGAAGTGATCTGCCAGGTTTATACTTGGGGAATGTGATTG	670
MOU	-----	670
HUM	-----T---G-A-----G---G-----GC-GC---C---C---CC-	658
	<b> Transmembrane region -----</b>	
RAT	ACTACAAGCAGAGTCTGGACAAAGGATTTTGGTTTTTCAGTCCCACTGCTGCTGAGCATTGTTTCTCT	737
MOU	-----T-----T---A-----	737
HUM	---TT-----A-CCG-CA-----C-A-----T---G---AT---A-----C---	725
	<b> Cytoplasmic region -----</b>	
RAT	GGTAATTCTTCTGGTCTTGATCTCCATCTTATTATACTGGAAACGGCACCAGAAATCAGGAGCGGGGT	804
MOU	-----A-----C-----T-----	804
HUM	-----C---C-A---A-----C-G-----T---G-----C---A---	792
RAT	GAGTCATCACAGGGGATGCAAAGAATGAAATAA	837
MOU	---A-----	837
HUM	---TG-----AG-T---A---C---	825

# FIGURE 8

Leader sequence—————

-30 -1

RAT M G S P V F R R P F C H L S T Y S L L W A I A A V A L S T A

MOU -----L-----I---G-----

HUM - I - M - - S - - - V - - V M - - - V - C - -

|V-like domain (domain I) ————— \*

RAT Q V E V V T Q D E R K L L H T T A S L R C S L K T T Q E P L

MOU -----A-----S-----

HUM ---Q-----E---Y-----K-----QNA---A---

31 \*\*

RAT I V T W Q K K K A V G P E N M V T Y S K A H G V V I Q P T Y

MOU -----S-----T-----A---

HUM -----E N-----

61 \*\* \*\*

RAT K D R I N I T E L G L L N T S I T F W N T T L D D G G C Y M

MOU -----V-----W--S-----H I G-----

HUM ---K-----Q-----Q---T-----I---E-----

91\* \*\* |C-like domain (domain II)—————

RAT C L F N M F G S G K V S G T A C L T L Y V Q P I V H L H Y N

MOU -----T-----Q-----

HUM -----F G---I-----V-----S-----K

121 \*\* \*

RAT Y F E H H L N I T C S A T A R P A P A I S W K G T G S G I E

MOU -----T-----T-----

HUM F S-----M V F-----V P R-----

151\*\*

RAT N S T E S H S H S N G T T S V T S I L R V K D P K T Q V G K

MOU -----F-----

HUM -----V T L S--P-----H I-----N-----

181 \* |Transmembrane region ———

RAT E V I C Q V L Y L G N V I D Y K Q S L D K G F W F S V P L L

MOU -----

HUM -----H---T--T--F---T V N---Y-----

211 |Cytoplasmic region —————

RAT L S I V S L V I L L V L I S I L L Y W K R H R N Q E R G E S

MOU -----I-----

HUM -----V-----D-----L

241

RAT S Q G M Q R M K


MOU -----

HUM -----V--K---T

\* invariant cysteine residues. \*\* invariant asparagine (N-linked oligosaccharides)




# FIGURE 9




CELLS added to C57BL/6 RESPONDER SPLEEN CELLS

# FIGURE 10




**FIGURE 11**




**NPC from Flt3 treated mice**

**FIGURE 12**




**FIGURE 13**




CELLS added to C3H RESPONDER SPLEEN CELLS


**FIGURE 14**



**FIGURE 15**




**FIGURE 16**





**FIGURE 17**



Monoclonal antibodies added to culture

FIGURE 18A






FIGURE 18B



# Effect of anti-OX2 on spontaneous abortions




Day of infusion of anti-OX2

## FIGURE 20

Effect of OX2:Fc on spontaneous abortions or renal allograft rejection

CBA with C57BL/6 grafts

$p < 0.02$   
\*



Day of infusion/no. doses of OX2:Fc

FIGURE 21


1

2

3



FGL 2




OX-2



**FIGURE 22**

# **EXPRESSION OF OX-2 ON CYTOKERATIN- POSITIVE CELLS (TROPHOBLAST)**



# EXPRESSION OF OX-2 ON CYTOKERATIN- POSITIVE CELLS (TROPHOBLAST)

